News

Company News & Events

ORYZON Selected as one of the Finalist for the 7th Annual Most Innovative EU Biotech SME Award

14 September 2016

BARCELONA, SPAIN and CAMBRIDGE MA.

Oryzon Genomics (Madrid Stock Exchange: ORY) (ISIN Code: ES0167733015), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today it has been selected as one of the 7 finalists by the European Association for Bioindustries (EuropaBio) for its Most Innovative European Biotech SME Awards. The other finalists nominated to this award include: Cellectis, TiGenix, OxyMem, MetGen, Biosyntia, and Plant Response Biotech. This year, 41 companies from 13 different European countries applied for this award.

Click here to see the full Press Release

Posted In: 
Investors
News

Share this story